skip to main content
Opens in a new window Opens an external site Opens an external site in a new tab
  • Network opens Gold Cohort to researchers for the first time through new pilot program
    Five research teams will use the Network’s robust dataset to accelerate research, while testing and validating our data access and use protocols

Other sites in our network

  • The Terry Fox Research Institute
  • Digital Health and discovery Platform (DHDP)
  • The Terry Fox Foundation
When autocomplete results are available use up and down arrows to review and enter to select.
  • Marathon of Hope Cancer Centres Network
  • The Terry Fox Research Institute
  • Digital Health and Discovery Platform (DHDP)
  • The Terry Fox Foundation
  • EN
  • FR
  • Watch us on YouTube
  • Join the Conversation on Bluesky
  • Join us on LinkedIn

MOHCC Logo and Wordmark

Donate
  • About Us
    • Mission and Vision
    • Funding model
    • Why Give
    • Contact Us
    • Careers
    • Governance structure
  • Our Network
    • Our People
    • Members and partners
    • Network Consortia
    • Working Groups
  • Our Research
    • Our Projects
    • The Promise of Precision Medicine
    • MOHCCN Gold Cohort
    • Innovation Infrastructure
    • Network Pilot Projects
  • News & Impact
    • News
    • Network Voices
    • Scientific publications
    • Videos and Media
  • Researcher Hub
    • Funding Opportunities
    • Policies and Guidelines
    • Administrative guidelines and templates
    • Logos, templates and visual guidelines
    • MOHCCN Seminar Series
  • Patient Hub

Susie Lau

Researcher
  • Segal Cancer Centre/Lady Davis Institute, Jewish General Hospital
Locations
  • Québec
Home > Our Network > Susie Lau

Projects

  • Abstract Canada network map

    Enabling precision oncology in rare types of gynecologic cancer

  • Exploring the perspectives of stakeholders for homologous recombination deficient (HRD) biomarker testing to guide precision medicine for advanced ovarian cancer treatment

  • Real-world determinants of response to combination Lenvatinib/Pembrolizumab in MMR-proficient advanced and/or recurrent endometrial cancer

  • Genomic profiling of HPV-independent vulvar cancer

MOHCC Logo
675 West 10th Avenue, 14th Floor, Vancouver, BC, Canada V5Z 1L3

P:604.675.8222|E:moh@tfri.ca

  • About Us
  • Our Network
  • Our Research
  • News & Impact
  • Researcher Hub
  • Patient Hub
Donate
  • Watch us on YouTube
  • Join the Conversation on Bluesky
  • Join us on LinkedIn

Supported By

TFRI Logo
Terry Fox Foundation

© 2024 The Marathon of Hope Cancer Centres Network. All rights reserved | Privacy and Terms

Designed and developed by Cubicle Fugitive